Updated Jul 16, 2026
Veness Adam M has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.42M.
Adam M. Veness is associated with Dianthus Therapeutics, Inc., a biotechnology company focused on developing innovative therapies for patients with serious diseases. Further details about his specific role or contributions to the company are not readily available.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale | 13.2K | $81.38 | $1.08M |
| 2026-06-18 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale | 16.8K | $80.34 | $1.35M |
| 2026-06-18 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise | 30.0K | $17.88 | $536K |
Adam M. Veness is associated with Dianthus Therapeutics, Inc., a biotechnology company focused on developing innovative therapies for patients with serious diseases. Further details about his specific role or contributions to the company are not readily available.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($2.42M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Veness Adam M profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.